Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, randomized, placebo-controlled, multicenter, dose-escalation study of oral modified-release omecamtiv mecarbil in chronic heart failure
2012-000327-40Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF), left ventricular systolic dysfunction (LVSD) and left ventricular failure (LVF) comparing Omecamtiv mecarbil MR with Placebo (2 arms). Primary endpoints: Formulation and dose selection (dose escalation phase) and Safety and tolerability of oral omecamtiv mecarbil. Started Jan 2013; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
chronic heart failure (CHF)left ventricular systolic dysfunction (LVSD)left ventricular failure (LVF)
Beyond the preview
Go deeper on 2012-000327-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000327-40.